Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model ...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
SUZHOU, China I 8, 2024 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...
SHANGHAI, China I December 04, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the new drug application (NDA) has been accepted by the National Medical Products Administration (NMPA) ...
SHANGHAI, China I December 4, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) announced that the investigational new drug (IND) application for a phase 1b/2 clinical trial of HLX43 for Injection, the ...
Following on from a period of exclusive evaluation announced in June 2024, Genmab has exercised its option to license an anti-glycan monoclonal antibody generated via Scancell’s proprietary GlyMab® ...
SOUTH SAN FRANCISCO, CA, USA I December 05, 2024 I Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the opening of ...
SOUTH SAN FRANCISCO, CA, USA I December 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...
STOCKHOLM, Sweden I December 5, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson’s ...
Multi-year effort leverages Muna’s all-in-human MiND-MAP spatial multi-omics approach to identify and validate new drug targets and treatment pathways for Alzheimer’s disease GSK secures option to ...